Skip to main content
Spero Therapeutics, Inc. logo

Spero Therapeutics, Inc. — Investor Relations & Filings

Ticker · SPRO ISIN · US84833T1034 LEI · 54930074G13LHWJT2323 US Manufacturing
Open in API
Filings indexed 481 across all filing types
Latest filing 2021-08-30 Director's Dealing
Country US United States of America
Listing US SPRO

About Spero Therapeutics, Inc.

https://sperotherapeutics.com/

Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections. The company's primary mission is to address the significant unmet medical needs caused by antibiotic resistance. Its pipeline includes tebipenem HBr, an oral carbapenem antibiotic candidate for the treatment of complicated urinary tract infections (cUTIs), which has completed a Phase 3 trial. Spero Therapeutics leverages its expertise in chemistry and microbiology, alongside strategic partnerships, to advance its portfolio of innovative therapies for serious infections.

Recent filings

Filing Released Lang Actions
FORM 4 SUBMISSION
Director's Dealing
2021-08-30 English
8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated August 26, 2021, by Spero Therapeutics, Inc. The content focuses on changes in executive officers' compensation, including salary increases and restricted stock unit awards. It specifically mentions the departure or appointment of officers and changes in their compensatory arrangements. There are no financial statements or detailed financial performance data included, nor is this a full annual or quarterly report. The primary subject is changes in management compensation and appointments, which aligns with the category for Board/Management Information (MANG). The document length is 5252 characters, which is sufficient to contain substantive information rather than a mere announcement. Therefore, the appropriate classification is MANG with high confidence.
2021-08-30 English
PRIMARY DOCUMENT
Director's Dealing
2021-08-27 English
PRIMARY DOCUMENT
Director's Dealing
2021-08-24 English
FORM 4 SUBMISSION
Director's Dealing
2021-08-18 English
FORM 4 SUBMISSION
Director's Dealing
2021-08-18 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.